Key result
Improving glucose oxidation and reducing epicardial fat may enhance myocardial efficiency and slow CVD progression.
Why the study?
This review aims to explain myocardial energy substrate adaptation, oxidative metabolism reduction and epicardial fat accumulation in pathological states, and potential therapeutic targets.
Therapies targeting epicardial fat volume and inflammation may improve myocardial oxidative metabolism and reduce cardiovascular disease progression by mitigating lipotoxicity and insulin resistance.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for metabolic therapies targeting epicardial fat; leaves open clinical efficacy in prospective trials.
The main energy substrate of adult cardiomyocytes for their contractility are the fatty acids. Its metabolism generates high ATP levels at the expense of high oxygen consumption in the mitochondria. Under low oxygen supply, they can get energy from other substrates, mainly glucose, lactate, ketone bodies, etc., but the mitochondrial dysfunction, in pathological conditions, reduces the oxidative metabolism. In consequence, fatty acids are stored into epicardial fat and its accumulation provokes inflammation, insulin resistance, and oxidative stress, which enhance the myocardium dysfunction. Some therapies focused on improvement the fatty acids entry into mitochondria have failed to demonstrate benefits on cardiovascular disorders. Oppositely, those therapies with effects on epicardial fat volume and inflammation might improve the oxidative metabolism of myocardium and might reduce the cardiovascular disease progression. This review aims at explain (a) the energy substrate adaptation of myocardium in physiological conditions, (b) the reduction of oxidative metabolism in pathological conditions and consequences on epicardial fat accumulation and insulin resistance, and (c) the reduction of cardiovascular outcomes after regulation by some therapies.
No takes yet. Share an insight, caveat, or question.
Gandoy-Fieiras et al. (2020) conducted a review in Cardiovascular disease and metabolic disorders. Metabolic therapies (e.g., SGLT2 inhibitors, GLP-1 agonists, trimetazidine) was evaluated. Therapies that improve glucose oxidative metabolism and reduce epicardial fat accumulation may enhance myocardial energy efficiency and reduce cardiovascular disease progression.
Synapse has enriched 10 related papers. Consider them for comparative context: